The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy

BACKGROUND: Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxiso...

Descripción completa

Detalles Bibliográficos
Autores principales: Treacy, Maxwell P, Hurst, Tara P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532122/
https://www.ncbi.nlm.nih.gov/pubmed/22937835
http://dx.doi.org/10.1186/1471-2415-12-46

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532122/
https://www.ncbi.nlm.nih.gov/pubmed/22937835
http://dx.doi.org/10.1186/1471-2415-12-46

Ejemplares similares